Drug Sales Trends for HUMULIN N

Annual Sales Revenues and Units Sold for HUMULIN N

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
HUMULIN N			2021
HUMULIN N			2020
HUMULIN N			2019
HUMULIN N			2018
HUMULIN N			2017
HUMULIN N			2016
HUMULIN N			2015

Human Recombinant Insulin Market Analysis: Focus on Humulin N

Introduction to Human Recombinant Insulin

Human recombinant insulin is a synthetic form of insulin produced through recombinant DNA technology, mimicking the natural insulin produced by the human body. This technology has revolutionized the treatment of diabetes, offering a more consistent and reliable source of insulin.

Market Size and Growth Projections

The global human recombinant insulin market is projected to grow significantly over the coming years. As of 2024, the market size is estimated at USD 28.47 billion and is expected to reach USD 32.20 billion by 2029, growing at a CAGR of greater than 2.9% during the forecast period[1].

Humulin N: An Overview

Humulin N is a type of intermediate-acting human recombinant insulin developed by Eli Lilly and Company. It is formulated to have a slower onset of action than regular insulin and a longer duration of activity, slightly less than 24 hours. This makes Humulin N a preferred choice for patients who require a more sustained insulin effect throughout the day.

Market Drivers for Humulin N

Increasing Prevalence of Diabetes

The rising prevalence of diabetes globally is a significant driver for the demand of human recombinant insulin, including Humulin N. According to the CDC, around 37.3 million people in the U.S. are living with diabetes, with 28.7 million diagnosed and 8.5 million undiagnosed cases[2].

COVID-19 Impact

The COVID-19 pandemic has highlighted the increased risk for diabetes patients, further driving the demand for insulin. Patients with diabetes are known to have an increased risk of severe COVID-19 infections, making insulin therapy more critical than ever[1].

Healthcare Expenditure

The increasing healthcare expenditure on insulin therapies is another key driver. For instance, the average out-of-pocket spending by Medicare Part D enrollees for Humulin R U-500 was USD 116 in 2022, indicating a significant investment in insulin products[1].

Market Segmentation and Humulin N

Drug Type

Humulin N falls under the category of intermediate-acting human insulin. This segment, while not as dominant as short-acting or long-acting insulins, still holds a significant market share due to its specific clinical benefits.

Brand Performance

Humulin, including Humulin N, is one of the major brands in the human recombinant insulin market. The brand has seen steady growth due to its reliability and the trust it has built among healthcare providers and patients. For example, the Humulin segment had a market value of USD 1283.7 million in 2021 and is anticipated to reach USD 1564.1 million by 2030, growing at a CAGR of 2.22%[4].

Regional Analysis

North America

North America, particularly the United States, is the largest market for human recombinant insulin, including Humulin N. This region accounts for a significant share of the global market due to high healthcare spending and a large diabetic population[1][2].

Asia Pacific

The Asia Pacific region is expected to be the fastest-growing market for human recombinant insulin. The increasing prevalence of diabetes in countries like China and India, coupled with improving healthcare infrastructure, is driving the growth in this region[1].

Competitive Landscape

The human recombinant insulin market is highly competitive, with major players such as Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon, and Zhuhai United Laboratories Co., Ltd. Eli Lilly and Company, the manufacturer of Humulin N, is one of the key players in this market, with a strong presence globally[1].

Sales Projections for Humulin N

Given the overall growth trends in the human recombinant insulin market, Humulin N is expected to see steady sales growth. Here are some key projections:

• Market Value: The Humulin segment, which includes Humulin N, is projected to grow from USD 1283.7 million in 2021 to USD 1564.1 million by 2030, at a CAGR of 2.22%[4].
• Regional Growth: In North America, where Humulin N has a strong presence, the insulin market is expected to reach USD 9,510.3 million by 2030, growing at a CAGR of 2.3% from 2025 to 2030[2].
• Global Impact: The global human insulin market, which includes Humulin N, is forecasted to exceed USD 46.7 billion by 2033, with a CAGR of 4.8% from 2024 to 2033[3].

Key Takeaways

• Growing Demand: The increasing prevalence of diabetes and the impact of COVID-19 are driving the demand for human recombinant insulin, including Humulin N.
• Market Growth: The global human recombinant insulin market is expected to grow significantly, with Humulin N contributing to this growth.
• Regional Focus: North America remains the largest market, while the Asia Pacific region is expected to be the fastest-growing.
• Competitive Landscape: Eli Lilly and Company, the manufacturer of Humulin N, is a major player in the highly competitive human recombinant insulin market.

FAQs

What is the current market size of the human recombinant insulin market?

The human recombinant insulin market size is estimated at USD 28.47 billion in 2024[1].

Which region has the largest share in the human recombinant insulin market?

North America accounts for the largest market share in the human recombinant insulin market[1].

What is the expected growth rate of the human recombinant insulin market from 2024 to 2029?

The market is expected to grow at a CAGR of greater than 2.9% from 2024 to 2029[1].

Which segment is the fastest-growing in the human recombinant insulin market?

The Asia Pacific region is the fastest-growing segment in the human recombinant insulin market[1].

What is the projected market value of the Humulin segment by 2030?

The Humulin segment is projected to reach USD 1564.1 million by 2030[4].

How does the COVID-19 pandemic impact the demand for Humulin N?

The COVID-19 pandemic has increased the risk for diabetes patients, thereby driving the demand for insulin, including Humulin N[1].

Last updated: 2024-12-31